Most breast cancers are fueled by estrogen, and anti-estrogenic agents often work for a time to control the cancers. But many of these cancers become resistant to the drugs for reasons that are not understood, leaving patients with limited treatment options. Now researchers say that this resistance appears to be due to a natural stress response in cells, and that the biochemical molecules involved in this response might prove to be a new drug target.